The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
about
PEGylated Adenoviruses: From Mice to MonkeysBispecific antibodies and their applicationsSite-Specific PEGylation of Therapeutic ProteinsDrug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systemsCarbohydrate PEGylation, an approach to improve pharmacological potencyDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorProtease-resistant peptide design-empowering nature's fragile warriors against HIVMolecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulationsFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In VivoBioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids.Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivoWhen 1+1>2: Nanostructured composites for hard tissue engineering applicationsA novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors.Fundamentals of translational neuroscience in toxicologic pathology: optimizing the value of animal data for human risk assessment.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacyFabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cellsThe development of bispecific antibodies and their applications in tumor immune escape.Improved Hemocompatibility of Multilumen Catheters via Nitric Oxide (NO) Release from S-Nitroso-N-acetylpenicillamine (SNAP) Composite Filled Lumen.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusAnti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity.Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.A Drug Carrier for Sustained Zero-Order Release of Peptide TherapeuticsSynthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.PEGylation enables the specific tumor accumulation of a peptide identified by phage display.Enhanced brain distribution of modified aspartoacylase.Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activitySpecies differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusPharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjectsPreferential Interactions and the Effect of Protein PEGylation.Sulfhydryl-specific PEGylation of phosphotriesterase cysteine mutants for organophosphate detoxification.High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation.Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro.
P2860
Q24635276-69FCFD11-1612-4028-9CB1-E04487AA9416Q26774024-611A84AC-5B9B-48FB-9E96-C6F89691BD1EQ26777819-3D37CC1E-8DA7-4FCE-BF63-879AC9B19A6CQ26798467-FEE61E7C-32BC-4645-B8D9-542E62081863Q27000494-0B5DB7B3-78E3-4C6A-A147-A104AEEA4E16Q27004054-5011251B-7C87-4ADA-8FF2-044C636AF96BQ27010058-CC27A036-0B8E-462F-9085-48C10833F32AQ28534725-86A66AB1-FF08-45B7-81E9-BBDE25E1183DQ28552652-5EF1F229-16DC-451E-93C6-99DE2F4BBBF7Q30279245-24782C62-98FB-4547-9AB7-0134E289EB4BQ30300201-04D21B02-E2FA-49FB-88A2-43B368D3CCFFQ30368848-70A755CF-D346-484D-AE43-6CE7FAFD0B0FQ30426130-1039018A-8EF1-413A-8E3B-6652EDBC3F30Q30468564-FE9E0731-2789-495F-BD37-D94C6248655EQ30869945-FB87935A-12C6-45AE-9391-E43EBA05CF14Q33586660-A2CC105A-042B-421A-BDE8-253D792DDE75Q33587331-A77C3C06-30D0-4F1F-90CD-78BF5CC8DE6FQ33630292-3413ED4D-5A27-46BC-B32A-781237A2A8EBQ33647184-25761045-418A-479A-85C4-08F6A179F528Q33690982-E816F4FA-2554-4F13-9674-DAC72B47B937Q33733451-16D059DC-4DA2-45A0-8B63-672760756174Q33763719-FC7BDC82-CF9B-4E8E-BF6C-BBD20ABB4768Q33873731-FC480B2F-760A-4243-B3C0-4462D65F3D66Q33912239-3A4F2619-F9DB-4C57-AD2B-BE99F7DC4385Q34001975-0489917D-21A3-45C2-8CB9-B6C9014682A3Q34096874-BB4F224B-4895-4FF3-936C-834CD6A7F52FQ34200694-24795C21-9036-437E-9ADC-9E78D7CDE73DQ34219669-0B7F07C6-DDBE-4896-B08C-BBBFFA5968BEQ34615563-7DB8A481-93E3-45B7-932E-616A31D57C7EQ34616189-6813C080-2846-4A22-8A3F-7E457F530B8DQ34919698-B2DCAA40-8641-4812-8866-4DB13230DD27Q34975214-0AF85A99-2B2E-4056-8AD2-45E22243AA24Q35135977-7F9B7222-823A-4C75-823F-98C7C14C37A8Q35286136-4D3CF81D-C31A-4E78-A2E0-3A9E84ABA23AQ35730064-44D13B54-1981-445E-9FF0-8EE0C9961FCFQ35738077-A1C1B105-ACDB-4808-B68A-E1E1A57AC0A4Q35757569-063F4263-0CE0-4FC4-9250-2C390BFA4C8BQ35803555-51CEE1C7-1F06-4CD0-94EE-DC45C0776842Q35963914-052E5483-3555-4DA0-8755-3C9BBFC33068Q35991894-4928C202-C0B1-4E81-AB47-257FAE6B8E26
P2860
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@en
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@nl
type
label
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@en
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@nl
prefLabel
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@en
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@nl
P356
P1476
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
@en
P2093
C Simone Fishburn
P304
P356
10.1002/JPS.21278
P407
P577
2008-10-01T00:00:00Z